1515
Annons
Elicera Therapeutics strengthens IP protection for ELC-100 through acquisition of patent from Immunicum

Gothenburg, January 5, 2021 - Elicera Therapeutics AB (publ) ("Elicera"), a clinical stage cell and gene therapy company that develops next generation immuno-oncological treatments based on enhanced oncolytic viruses and CAR T-cells, today announced that it has acquired patent US 9,017,672 B2 - a viral vector used in its candidate ELC-100 - from Immunicum. The transfer of the patent amounts to a total of 250,000 EUR in payments, excluding potential milestones. The acquisition further strengthens the IP protection of ELC-100, Elicera's most advanced project.

The patent for the viral vector used in ELC-100 is currently owned by Immunicum and out licensed to Elicera. The remuneration for the transfer of the patent from Immunicum to Elicera is an upfront payment of 175,000 EUR with an additional annual payment of 25,000 EUR over the next three years, excluding potential milestone payments according to the terms of the agreement in connection to conclusion of future clinical studies.

The agreement further states that Elicera will grant a world-wide non-exclusive license to Immunicum for the purpose of using the viral vector to label immune cells or tumor cells with exogenous antigens for therapeutic purposes. Elicera's ownership of the patent also opens up future opportunities to create new oncolytic viruses based on the same virus vector. 

Any prior agreements with Immunicum, including mutual royalties, have been terminated.

- A strong patent portfolio for our clinical development program is of highest strategic importance, and the acquirement of the patent for the viral vector used in ELC-100, our most advanced project, gives us full control over the candidate's IP protection. It will also facilitate negotiations with potential partners for ELC-100, said Jamal El-Mosleh, CEO of Elicera.

About ELC-100
Elicera's oncolytic virus ELC-100 is based on a genetically modified adenovirus that has been optimized with regards to its ability to selectively infiltrate and replicate in neuroendocrine cancer cells but not in healthy cells. When new virus particles have formed in enough numbers, the tumor cells burst through a so-called immunogenic oncolysis. ELC-100 is currently being used in an ongoing clinical phase I/II-study in the treatment of neuroendocrine tumors.

Source: Cision
Tillbaka

Det verkar som att du använder en annonsblockerare

Om du är prenumerant behöver du logga in för att fortsätta. Vill bli prenumerant kan du läsa Di Digitalt för 197 kr inkl. moms de första 3 månaderna.

spara
1090kr
Prenumerera